Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Lags Revenue Estimates

While Lyra Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? Lyra Therapeutics, Inc. (LYRA) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of$0.15. This compares to loss of $0.35 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 20%. A quarter ago, it was expected that this company would post a ...